SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--

Exelixis, Inc. (Nasdaq:EXEL) announced today that it will present 15 posters on the company's investigational compounds at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer Therapeutics," which will be held October 21-October 24 in Geneva, Switzerland. The titles, schedules, and locations for the poster presentations are provided below. Note that this information is also available on the EORTC website.

WEDNESDAY, October 22
----------------------------------------------------------------------
Location: Poster Hall
Time: 12 noon-2:15 pm

Topic: Biomarkers (PP57)
Evaluation of peripheral blood cells and hair as surrogate tissues for clinical trial pharmacodynamic assessment of XL147 and XL765, inhibitors of the PI3K signaling pathway
Poster #89

Analysis of EGFR and KRAS mutations in circulating tumor DNA (cTDNA) from plasma of NSCLC patients in phase 2 trials of XL647
Poster #97

Topic: Heat shock proteins (PP26)
XL888, a novel, synthetic, orally bioavailable inhibitor of HSP90
Poster #144

Topic: Phase 2 (PP44)
A phase 2 study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
Poster #212

Topic: PI3Kinase (PP45)
A phase 1 dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors
Poster #216

A phase 1 dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
Poster #218

THURSDAY, October 23
----------------------------------------------------------------------
Location: Poster Hall
Time: 12 noon-3:00 pm

Topic: New Molecular Targets (PP35)
Identification of XL413, a selective Cdc7 kinase inhibitor which induces cell cycle arrest and exhibits potent antitumor activity
Poster #339

Identification of potent, selective sphingosine-1-phosphate 1 receptor (S1P1R) antagonists with antitumor activity
Poster #335

Topic: Phase 1 (PP43)
A phase 1 study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)
Poster #379

A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients with advanced solid tumors
Poster #383

A phase 1 dose-escalation study of XL228, a potent IGF1R / Src inhibitor, in patients with advanced malignancies
Poster #390

Phase 1 study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies
Poster #395

Topic: mTOR (PP33)
mTORC1/mTORC2 selective inhibitors: Identification and characterization of novel small molecules with anti-tumor activity
Poster #322

Topic: Cyclins and CDK's (PP14)
Discovery of selective CDK9 small molecule inhibitors: CDK9 inhibition in tumor cells is associated with inhibition of proliferation and induction of apoptosis
Poster #291

FRIDAY, October 24
----------------------------------------------------------------------
Location: Poster Hall
Time: 12 noon-2:00 pm

Topic: Signal Transduction Modulators (PP38)
Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor (TKI) resistance in NSCLC: impact of preclinical studies on clinical trial design
Poster #552

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.

Source: Exelixis, Inc.